the patients have been followed up for a minimum of 5 years and 52 per cent of patients in the control group , 44 per cent of the 5fu group and 32 per cent of the 5fu/levamisole group have died of tumour recurrence .
C0016360
5fu
C0279296
5fu/levamisole